Search
tarlatamab (AMG 757)
Indications:
- investigational agent for treatment of small cell lung carcinoma in patients previously treated with platinum-based regimen & anti PD-1)/PD-L1 antibodies [1]
Dosage:
- 0.003-100 mg IV presumptively by infusion every 2 weeks
Pharmacokinetics:
- mean terminal elimination 1/2 life ia 5.7 days
Adverse effects:
- cytokine release syndrome (52%)
- pyrexia in 43 patients (40%)
- constipation in 33 patients (31%)
Mechanism of action:
- novel bispecific T cell engagenovel bispecific T cell engager
- binds to delta-like ligand 3 (DLL3) on tumor cells & cluster of differentiation 3 (CD3) on T cells, triggering T cell-dependent antitumor immunity
- DLL3 is an inhibitory Notch ligand highly expressed in SCLC & other neuroendocrine tumors, but minimally expressed in normal tissues
Notes:
- median progression-free survival: 3.7 months
- median overall survival: 13.2 months
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Tang D, Kang R
Tarlatamab: The Promising Immunotherapy on Its way From the Lab to the Clinic.
Transl Lung Cancer Res. 2023;12(6):1355-1357.
PMID: 37425422 PMCID: PMC10326778 Free PMC article
https://www.medscape.com/s/viewarticle/994563